Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Targeted Therapies for Bladder Cancer and Beyond: Overview and Current Status of FGFR Inhibitors

Ignacio Duran, MD, PhD
Released: June 14, 2021
Back Next


  1. Isharwal, S, B Konety. Non-muscle invasive bladder cancer risk stratification. Indian J Urol. 2015;31:289-296.
  2. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin‐based chemotherapy. Lancet Oncol. 2011;12:211‐214.
  3. Patel, VG, Oh, WK, et al. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404‐423.
  4. Dietrich B, Siefker-Radtke AO, Srinivas S, et al. Systemic therapy for advanced urothelial carcinoma: current standards and treatment considerations. Am Soc Clin Oncol Educ Book. 2018;38:342-353.
  5. Armelin HA. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci U S A. 1973;70:2702-2706.
  6. Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem. 1975;250:2515-20.
  7. Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215.
  8. Turo R, Harnden P, Thygesen H, et al. FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases. J Urol. 2015;193:325.
  9. Wu, X. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713
  10. Huhtala MT, Pentikäinen OT, Johnson MS. A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding. Structure. 1999;7:699-709.
  11. Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer. 2010;10:116-29.
  12. Itoh N, Ohta H, Konishi M. Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front Endocrinol (Lausanne). 2015;6:154.
  13. Liu G, Chen T, Ding Z, et al. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif. 2021;54:e13009.
  14. Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318-332.
  15. Costa R, Carneiro BA, Taxter T, et al. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016;7:55924-55938.
  16. Krook MA, Reeser JW, Ernst G, Barker H, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124:880-892.
  17. Erdafitinib [prescribing information]. Horsham, PA: Janssen Products, LP; 2019.
  18. Pemigatinib [prescribing information]. Wilmington, DE: Incyte Corporation; 2020.
  19. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 2019;381:338-348.
  20. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21;671-684.
  21. Necchi A, Castellano DE, Mellado B, et al. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2019. Abstract 409.
  22. Siefker-Radtke AO, Currie G, Abella E, et al. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2020. Abstract 4511.
  23. Catenacci DVT, Rasco D, Lee J, et al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020;38:2418-2426.
  24. Catenacci DV, Tesfaye A, Tejani M, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT phase III study design. Future Oncol. 2019;15:2073-2082.
  25. Trudel S, Bergsagel PL, Singhal S, et al. A phase I study of the safety and pharmacokinetics of escalating doses of MFGR1877S, a fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with relapsed or refractory t(4;14)-positive multiple myeloma. Presented at: 2012 American Society of Hematology Annual Meeting; December 8-11. Abstract 4029.
  26. Presta M, Chiodelli P, Giacomini A, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171-187.
  27. Tolcher AW, Papadopoulos KP, Patnaik A, et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol. 2016;27:526-532.
  28. Ronca R, Giacomini A, Di Salle E, et al. Long-pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell. 2015;28:225-39.
  29. Castelli R, Giacomini A, Anselmi M, et al. Synthesis, structural elucidation, and biological evaluation of NSC12, an orally available fibroblast growth factor (FGF) ligand trap for the treatment of FGF-dependent lung tumors. J. Med. Chem.2016;59:4651-4663.
  30. Kim SB, Meric-Bernstam F, Kalyan A, et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody–drug conjugate (BAY 1187982) in patients with advanced cancer. Targ Oncol. 2019;14:591-601.
  31. Surguladze D, Pennello A, Ren X, et al. LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions. Presented at: 2019 American Association for Cancer Research Annual Meeting; March 29-April 3. Abstract 4835.
  32. Bahleda R, Italiano A, Hierro C, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25:4888-4897.
  33. Rodriguez-Vida A, Saggese M, Hughes S, et al. Complexity of FGFR signalling in metastatic urothelial cancer. J Hematol Oncol. 2015;24;8:119.
  34. Li Q, Bagrodia A, Cha EK, et al. Prognostic genetic signatures in upper tract urothelial carcinoma. Curr Urol Rep. 2016;17:12.
  35. Siefker-Radtke AO, Necchi A, Park SH, et al. Presented at: 2018 American Society of Clinical Oncology Annual Meeting 2018. June 1-5. Abstract 4503.
  36. van der Noll R, Leijen S, Neuteboom Get al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev. 2013;39:664-672.
  37. Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol. 2016;27:998-1005.
  38. Wöhrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011;26:2486-2497.
  39. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671-684.
  40. Siefker-Radtke A, Loriot Y, Siena S, et al. Updated data from the NORSE trial of erdafitinib plus cetrelimab in patients with metastatic or locally advanced urothelial carcinoma and specific fibroblast growth factor receptor alterations. Presented at: 2020 European Society for Medical; September 18-22. Abstract 752P
  41. Moreno V, Loriot Y, Valderrama BP, et al. Dose escalation results from phase 1b/2 NORSE study of erdafitinib plus checkpoint inhibitor JNJ-63723283 (cetrelimab) in patients with metastatic or surgically unresectable urothelial carcinoma and selected fibroblast growth factor receptor gene alterations. Presented at: 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 13-15. Abstract 3055.
  42. ClinicalTrials.gov. A study of erdafitinib versus investigator choice of intravesical chemotherapy in participants who received bacillus Calmette-Guérin (BCG) and recurred with high risk non-muscle-invasive bladder cancer (NMIBC). clinicaltrials.gov/ct2/show/NCT04172675. Accessed May 24, 2021.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Pharmaceutica NV

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings